title: Factor VIII concentrate prepared from blood donors stimulated by intranasal administration of a vasopressin analogue.
abstract: With an interval of eight weeks between collections, blood was drawn twice from 120 blood donors. At one of the donations, 0.25 ml of synthetic vasopressin, (DDAVP, 1300 micrograms/ml), was administered intranasally 60 minutes prior to collection of the blood. No drug was given at the other donation. The yield of factor VIII clotting activity (VIII:C) and factor VIII antigen (VIIIR:Ag) was compared in blood drawn from the treated and untreated donors. To prevent degradation of VIII:C by fibrinolysis, tranexamic acid was added to the plasma from treated donors immediately after separation from the red blood cells. Plasma from treated donors and the derived Cohn fraction I-O contained approximately twice as much VIII:C as plasma and fraction I-O from untreated control donors. The concentration of VIIIR: Ag was also increased in fraction I-O made from plasma from treated donors, however to a lesser degree. The in vivo properties of factor VIII concentrates made from each group of donors were studied. Half-life in plasma and recovery of VIII:C were identical. Thus, intranasal synthetic vasopressin may be used to increase the yield of VIII:C in production of factor VIII concentrates.
mesh_terms: D000281:Administration, Intranasal; D001127:Arginine Vasopressin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D001782:Blood Donors; D001800:Blood Specimen Collection / Q000379:methods; D004912:Erythrocytes / Q000032:analysis; D005169:Factor VIII / Q000302:isolation & purification* / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D008297:Male
chemical_list: D001127:Arginine Vasopressin; C030027:argipressin, AlaNH2(9)-; D005169:Factor VIII